Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Open accessThe DOI matches its Crossref record; 162 of the 167 references it cites were found in a registry or an index; 110 of the 165 sources its claims cite were checked for support.
Abstract
The innovative development of nanomedicine has promised effective treatment options compared to the standard therapeutics for cancer therapy. However, the efficiency of EPR-targeted nanodrugs is not always pleasing as it is strongly prejudiced by the heterogeneity of the enhanced permeability and retention effect (EPR). Targeting the dynamics of the EPR effect and improvement of the therapeutic effects of nanotherapeutics by using EPR enhancers is a vital approach to developing cancer therapy. Inadequate data on the efficacy of EPR in humans hampers the clinical translation of cancer drugs. Molecular targeting, physical amendment, or physiological renovation of the tumor microenvironment (TME) are crucial approaches for improving the EPR effect. Advanced imaging technologies for the visualization of EPR-induced nanomedicine distribution in tumors, and the use of better animal models, are necessary to enhance the EPR effect. This review discusses strategies to enhance EPR effect-based drug delivery approaches for cancer therapy and imaging technologies for the diagnosis of EPR effects. The effort of studying the EPR effect is beneficial, as some of the advanced nanomedicine-based EPR-enhancing approaches are currently undergoing clinical trials, which may be helpful to improve EPR-induced drug delivery and translation to clinics.
Overview
CoChat Summary
## TL;DR
This review argues that EPR-based nanodrug delivery is promising but highly variable in humans because tumor vasculature, extracellular matrix, and the tumor microenvironment are heterogeneous. It surveys pharmacological, physical, and imaging-based strategies to improve EPR and emphasizes that personalized, model-appropriate, multimodal approaches are needed for clinical translation.
## Key findings
- The paper identifies two broad classes of EPR-enhancing strategies: pharmacological approaches that alter the tumor microenvironment, and physical approaches using external stimuli such as heat, radiation, photodynamic therapy, and ultrasound.
- It reports several quantitative examples from prior studies: tissue plasminogen activator pretreatment increased penetration of 115 nm nanoparticles in A549 xenograft mice; DC101 plus chemotherapy produced an approximately threefold accumulation increase of smaller nanoparticles; a cediranib plus size-changeable gold nanoparticle strategy produced about a twofold increase in tumor size suppression; liposomal doxorubicin plus NaHCO3 increased drug uptake by 21-fold in a TNBC mouse model.
- The review cites literature estimating that only 0.7% of systemically administered nanoparticles reach tumors, and that only 0.1% to 0.2% of the injected dose is effective against tumor cells with significant anticancer effects.
- It highlights a major controversy: one cited study found that around 97% of nanoparticles may enter tumors via active transcytosis rather than passive transport through endothelial gaps.
## Methods
- This is a narrative review of published work on EPR-based drug delivery for cancer therapy and diagnosis, organized around strategies to enhance EPR, tumor microenvironment targeting, imaging, challenges, and clinical translation.
- The paper synthesizes evidence from preclinical animal models, some clinical studies, and imaging studies, and discusses specific examples of nanoparticles, drugs, and EPR enhancers reported in the literature.
- Its main analysis is comparative and conceptual rather than experimental: it classifies strategies, summarizes reported outcomes, and argues for multimodal imaging and better animal models to evaluate EPR more accurately.
## Limitations
- The paper explicitly states that data on the efficacy of EPR in humans are inadequate, which hampers clinical translation.
- It also states that EPR is highly heterogeneous across tumor types, sizes, sites, and patients, so one-size-fits-all approaches are inadequate.
- Evident from the text: the paper is a review and does not present original experimental data, so its conclusions depend on the quality and consistency of the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Pharmacological approaches to improve EPR effect. (A). Vascular normalizer to improve the blood flow, (B). Fibrinolytics co-therapy, (C). Enhanced permeability of endothelial cells using vascular mediators, (D). Stromal density decreases by ECM degradation, (E). Tumor-penetrating peptides enhance transcytosis. Reprinted with permission from [23]. Copyright (2023), with permission from Elsevier.](https://figures.cochat.ai/paper-figures/d8d57d6e81b946b5aac7f395fbf5f7ca/approaches-to-improve-epr-based-drug-delivery-for-cancer-therapy-and-diagnosis-figure-1.jpg)
![Figure 2 Strategies to enhance EPR-based drug delivery targeting the tumor microenvironment. Adapted with permission from [17].](https://figures.cochat.ai/paper-figures/6ea3df71c40a4cc0967de3efe05abf30/approaches-to-improve-epr-based-drug-delivery-for-cancer-therapy-and-diagnosis-figure-2.jpg)
![Figure 3 Imaging NP pharmacology and the EPR effect across multiple spatial and temporal scales. (A) Pharmacokinetics and pharmacodynamics (PK/PD) of NPs (B). Imaging strategies and (C) IVM modalities are particularly suitable for imagining dynamic and microscopic courses of the EPR effect and the TME. Adapted with permission from [18].](https://figures.cochat.ai/paper-figures/f1710454586346b5b4ef8dabd7eb4ef5/approaches-to-improve-epr-based-drug-delivery-for-cancer-therapy-and-diagnosis-figure-3.jpg)
Verification
Claims the paper makes
76 Valid · 10 Not valid · 36 Not checked · 33 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In clinical settings, this approach has been proven to be ineffective when used alone [23].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 2. Major Advances and Emerging Concepts of EPR-Enhancing Strategies > 2.2. Normalization of Vasculature One of the classical approaches is to administer antiangiogenic compounds and deprive the tumor tissue of oxygen and nutrients. In clinical settings, this approach has been proven to be ineffective when used alone [23]. Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment. An intermediate dose of anti-VEGF receptor two antibodies (DC101) was used to successfully normalize the blood vasculature in and around the tumor site, thereby reducing the necrotic and hypoxic regions [25]. Further, the research group administered a combination of Doxil (around 125 nm in size) or Abaxane (around 12 nm in size) in breast tumor-bearing mice and observed a significant (around threefold) accumulation of smaller nanoparticles [26]. This concludes the DC101 improved tumor vascular normalization leading to a smaller and homogenous pore on the tumor vessel wall [25]. Another class of drugs used to aid in vascular normalization is tyrosine kinase inhibitors (TKIs), a small molecule class of drugs. Several research groups employed treatment with erlotinib, an EPR enhancer which is a TKI against epidermal growth factor receptor (EGFR). This improved the accumulation of human serum albumin-bound paclitaxel (HAS-PTX) in vivo in tumor-bearing mice such as head and neck carcinoma cells (SCC7), colon carcinoma cells (CT26), and breast cancer cells (4T1) [27]. A significant tumor size reduction was observed in models with combination therapy of erlotinib and has-PTX in comparison to the HAS-PTX group alone. A higher vascular normalization resulted in a higher distribution of hasHSA-PTX to the tumor site. Another TKI, Imatinib, inhibits VEGF-independent angiogenesis and also improves the delivery of nanoparticles to the tumor site, which was observed in A459 xenograft tumor models (lung carcinoma) [28]. Most research groups have reported that vascular normalization results in pore size reduction in the tumor vasculature. One of the problems with vascular normalization is the accumulation and quick clearance of small-sized nanoparticles. Research groups such as Xiao et al. used a combination of cediranib (VEGFR TKI) and enzyme-responsive size changeable gold nanoparticles (from around 40 nm to 300 nm upon enzymatic activity) [29]. The size-changeable gold nanoparticles have shown an around twofold increase in the tumor size suppression in the subcutaneous 4T1 tumor model than the fixed size nanoparticles. The increase in size led to increased residence time in the tumor tissue and improved the antitumor effect of size-changeable gold nanoparticles that increased with the coadministration of cediranib. In addition, celecoxib a cyclooxygenase-2 (COX-2) inhibitors also act as an angiogenesis inhibitor and result in vascular normalization and improved EPR effect in the tumor site [30]. The choice of therapy for vascular normalization must be chosen wisely since this approach is effective in delivering small-sized nanomedicines in comparison to the larger ones.
What the sources say
- Disputedcites [23] Carmeliet, 2011, Molecular mechanisms and clinical applications of angiogenesis, Nature sourceExperimental — accuracy not yet measured
The section ‘Clinical anti-angiogenesis with VEGF blockers’ says VEGF receptor TKIs are effective as monotherapy in certain cancers, although they fail in others. That directly contradicts the unqualified claim that antiangiogenic treatment has been proven ineffective when used alone in clinical settings. Page numbers were not provided in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The other mechanical pressures and physical barriers due to the rapid growth of tumor mass may also contribute to the heterogeneity of the EPR effect and declined efficiency of nanotherapeutics in human tumors [103].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 4. Dynamics of the EPR Effect and Strategies to Improve the Therapeutic Effects of Nanomedicines by Using EPR Effect Enhancers > 4.1. Dynamics and Heterogeneity of Vascular Structures in Human Tumors
What the sources say
- Disputedcites [103] Maeda, 2018, Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs, Clin. Transl. Med. sourceExperimental — accuracy not yet measured
In “Problems with cancer drug screening and safety in rats and mice” (page unavailable), the paper describes growth-induced physical pressure as an artifact of rapidly growing mouse tumors, not a feature comparable to human tumor growth. It says human tumors usually grow much more slowly. This runs contrary to the claim’s proposed rapid-growth pressure mechanism in human tumors; the passage does not assess its proposed effect on EPR heterogeneity. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Breast cancer tumors developed in mice were investigated by CA-MSI using Gadoteridol, revealing tumor margins and vasculature by localizing the contrast agents.”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 5. Applications of Advanced Imaging Technologies for Visualization and Quantification of EPR-Induced Nanomedicine Distribution in Tumors
What the sources say
- Not checked — no full text of the sourcecites [145] Tata, 2015, Contrast Agent Mass Spectrometry Imaging Reveals Tumor Heterogeneity, Anal. Chem. source
- Disputedcites [146] Abdelmoula, 2019, Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data, Anal. Chem. sourceExperimental — accuracy not yet measured
The Materials and Methods and Results describe a mouse brain glioblastoma model studied with MALDI MSI and MRI after administration of erlotinib—not breast tumors investigated with Gadoteridol. The Results map drug and tumor-associated molecular signals but do not report localizing a contrast agent to reveal tumor margins or vasculature. Page numbers were not provided in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A recent study by Chan W.C.W et al. demonstrated that inter-endothelial gaps in tumors may not be responsible for the transport of nanodrugs into solid tumors [161].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 7. Challenges of EPR-Based Drug Delivery into Solid Tumors
What the sources say
- Disputedcites [161] Golombek, 2018, Tumor targeting via EPR: Strategies to enhance patient responses, Adv. Drug Deliv. Rev. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says that wide openings in tumor blood vessels allow nanomedicines to leave the vessels. The Anti-angiogenic therapy section (page unavailable) specifically says that closing gaps between endothelial cells limits drug delivery. Rather than reporting the attributed finding, this source describes those gaps as a route for transport into tumors. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Contrary to the EPR mechanism, the frequency of the gaps on the endothelial lining in tumors is too low to account for the NP accumulation in the tumor site, which was observed by TEM analysis [161].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 7. Challenges of EPR-Based Drug Delivery into Solid Tumors
What the sources say
- Disputedcites [161] Golombek, 2018, Tumor targeting via EPR: Strategies to enhance patient responses, Adv. Drug Deliv. Rev. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says abnormally wide tumor-vessel fenestrations allow nanomedicines to leave the bloodstream and, with absent lymphatic drainage, accumulate in tumors. The Principles of EPR section likewise describes vascular leakiness as a basis for tumor targeting. The paper does not report the claimed TEM finding that endothelial gaps are too infrequent to account for accumulation. (LLM, conf=0.83)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
88 more claims · 56 with their cited sources checked
Create a free account to see all 155 claims and to verify the 2 references still open.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Parveen, 2022, Investigation of Eutectic Mixtures of Fatty Acids as a Novel Construct for Temperature-Responsive Drug Delivery, Int. J. Nanomed., 17, 2413, 10.2147/IJN.S359664”
Cited work 10.2147/ijn.s359664 · retracted 2023-11-07 · notice 10.2147/ijn.s448407 · this paper published 2023-02-23
Citations
Cites
1 retracted
Parveen, F., Madni, A., Torchilin, V. P., Rehman, M., Jamshaid, T., Filipczak, N., Rai, N., Khan, M. M., & Khan, M. I. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s359664 · Cited by 13
Self-citationRetractedNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“, have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
MethodMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 1×
“In clinical settings, this approach has been proven to be ineffective when used alone [23].”
MethodAnalysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · cited 1×
“7% NPs that were administered systemically reach tumors [160].”
BackgroundRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationProgress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
Blom, J. W. (2005) · JAMA · doi:10.1001/jama.293.6.715 · Cited by 1,949
Mechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871 · cited 1×
“The HIF-1α gene is translated into the HIF-1α protein, which is allied with the stimulation of a series of genes that may worsen the tumor state [62].”
BackgroundThe entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732 · cited 1×
“Transcytosis is a metabolically active process that necessities endothelial cells to reorganize their cytoskeleton and cell membrane, involving vesicle formation transporting NPs through the cytoplasm [123,162].”
BackgroundGlycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516 · cited 1×
“This decreased pH of TME can be utilized to deliver pH-responsive NPs to release drugs at a low pH [1,5,6].”
BackgroundEmerging functions of the EGFR in cancer
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,469 · cited 1×
“Overexpression of EGFR is detected in different cancer cells, which is involved in several molecular and cellular pathways including apoptosis inhibition [49].”
BackgroundDanhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288 · cited 1×
“Optimization of nanomedicine design to enhance the EPR effect is also one of the strategies that are proposed, as well as a combination of the nanomedicine with the external stimuli, including ultrasounds, radiotherapy or hyperthermia or usage of nanomedicine modified with the cell-penetrating peptides [157].”
BackgroundTumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262 · cited 4×
“2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
BackgroundInfluentialNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“i lt t itigation of tumor heterogeneity and vasculature, normalizing disorganized tumor v sculature, and unblocking the occlud d vessels are the two m in approaches in achieving uniform d ug delivery to th tumor site as shown in Figure 1 [13,21,22].”
BackgroundMethodChallenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 2×
“An intermediate dose of anti-VEGF receptor two antibodies (DC101) was used to successfully normalize the blood vasculature in and around the tumor site, thereby reducing the necrotic and hypoxic regions [25].”
BackgroundMethodThe Role of CT Pulmonary Angiography in the Investigation of Unilateral Pleural Effusions
Hooper, C., Laurence, I., Harvey, J., Morley, A., Darby, M., Edey, A., & Maskell, N. (2014) · Respiration · doi:10.1159/000347003 · Cited by 1,184
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179 · cited 2×
“i lt t itigation of tumor heterogeneity and vasculature, normalizing disorganized tumor v sculature, and unblocking the occlud d vessels are the two m in approaches in achieving uniform d ug delivery to th tumor site as shown in Figure 1 [13,21,22].”
BackgroundMethodChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101 · cited 1×
“Further, the research group administered a combination of Doxil (around 125 nm in size) or Abaxane (around 12 nm in size) in breast tumor-bearing mice and observed a significant (around threefold) accumulation of smaller nanoparticles [26].”
MethodAttia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085 · cited 1×
“This decreased pH of TME can be utilized to deliver pH-responsive NPs to release drugs at a low pH [1,5,6].”
BackgroundNanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Wu, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080771 · Cited by 1,030
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931 · cited 1×
“Remodeling of TME focused on the biological modification of the structural characteristics of tumors and their environment to improve nanodrug delivery to the target tumor cells [44,79].”
BackgroundShi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868 · cited 2×
“radioisotopes were used for imaging and radiotherapy of cancerous lesions by manipulating EPR-based aggregation in the tumors [121].”
BackgroundMethodNichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834 · cited 1×
“Further, preclinical animal models of tumors usually overrate the EPR effect compared to tumors in humans, which obscures the clinical advancement of nanodrugs [125].”
BackgroundNam, J., Son, S., Ochyl, L. J., Kuai, R., Schwendeman, A., & Moon, J. J. (2018) · Nature Communications · doi:10.1038/s41467-018-03473-9 · Cited by 808
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757 · cited 3×
“i lt t itigation of tumor heterogeneity and vasculature, normalizing disorganized tumor v sculature, and unblocking the occlud d vessels are the two m in approaches in achieving uniform d ug delivery to th tumor site as shown in Figure 1 [13,21,22].”
BackgroundMethodDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Vakoc, B. J., Lanning, R. M., Tyrrell, J. A., Padera, T. P., Bartlett, L. A., Stylianopoulos, T., Munn, L. L., Tearney, G. J., Fukumura, D., Jain, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.1971 · Cited by 719 · cited 1×
“As a result, vasculature remodeling utilizing a drug delivery system has been a prospective approach [88,89].”
BackgroundAntigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., Chai, S., Herring, L. E., Zhang, L., Zhang, T., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.113 · Cited by 701 · cited 1×
“Thus, the enhancement of the EPR effect by PDT, SDT, and RT with the nanodrugs has synergistically improved anticancer therapy [78].”
BackgroundRecent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623 · cited 2×
“2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
BackgroundSelf-citationRecent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591 · cited 1×
“Further, the regulation of tumor blood vessels in TME may be attained by the delivery of anti-VEGF antibodies or VEGF receptor inhibitors [93,94].”
BackgroundThe Hypercoagulable State of Malignancy: Pathogenesis and Current Debate
Caine, G. J., Stonelake, P. S., Lip, G. Y. H., & Kehoe, S. T. (2002) · Neoplasia · doi:10.1038/sj.neo.7900263 · Cited by 576 · cited 1×
“Cancer mortality and morbidity are contributed to by a hypercoagulative state of malignancy in patients [31].”
BackgroundCombining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506 · cited 1×
“Tumors in humans are poorly diagnosed in the initial stages, which is mainly responsible for the limiting effects of EPR after drug release [102].”
BackgroundMaeda, H., & Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0185-6 · Cited by 491
Pittet, M. J., & Weissleder, R. (2011) · Cell · doi:10.1016/j.cell.2011.11.004 · Cited by 466 · cited 1×
“These new modalities will likely extend possibilities for the imaging of nanodrugs [147,148].”
BackgroundHeterogeneity of the Tumor Vasculature
Nagy, J., Chang, S.-H., Shih, S.-C., Dvorak, A., & Dvorak, H. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1253454 · Cited by 422 · cited 1×
“As a result, vasculature remodeling utilizing a drug delivery system has been a prospective approach [88,89].”
BackgroundKano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410 · cited 1×
“A low dose of TGF-β inhibitor effectively modified TME, tumor vasculature, and enhanced the EPR effect [87].”
BackgroundPark, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382 · cited 2×
“As a result, novel approaches are required to advance EPR-based drug delivery in tumors [17].”
BackgroundStrategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330 · cited 1×
“The inhibitory effects of this enzyme mediate the release of bradykinins, a major player of KKS through kinin receptors [106].”
BackgroundGao, R., Mei, X., Yan, D., Liang, R., & Wei, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05223-3 · Cited by 307 · cited 2×
“Nanophotosensitizers, isophthalic acid/layered double hydroxide, and hybrid nanosystems exhibited enhanced cytotoxicity with significantly a low IC50 value and safety profile, which was allied with a higher EPR effect [59].”
BackgroundEnzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298 · cited 1×
“HA-degradable PEGPH20 in integration with gemcitabine has demonstrated enhanced therapeutic effects in animal models [56,57].”
BackgroundClinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3
Chen, H., Niu, G., Wu, H., & Chen, X. (2016) · Theranostics · doi:10.7150/thno.13242 · Cited by 282 · cited 1×
“Integrin is a tumor-specific marker of angiogenic function in ECM among the transmembrane factors [45].”
BackgroundHansen, A. E., Petersen, A. L., Henriksen, J. R., Boerresen, B., Rasmussen, P., Elema, D. R., Rosenschöld, P. M. A., Kristensen, A. T., Kjær, A., & Andresen, T. L. (2015) · ACS Nano · doi:10.1021/acsnano.5b01324 · Cited by 277 · cited 1×
“, using canine spontaneous tumors that closely mimic the human condition and 64Cu-labeled liposomes that can be imaged with positron emission tomography, showed that rapidly growing tumors such as carcinomas are highly vascularized and therefore have more porous and leaky blood vessels, while slow-growing tumors, such…”
BackgroundIntravital imaging by simultaneous label-free autofluorescence-multiharmonic microscopy
You, S., Tu, H., Chaney, E. J., Sun, Y., Zhao, Y., Bower, A. J., Liu, Y.-Z., Marjanovic, M., Sinha, S., Pu, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04470-8 · Cited by 271 · cited 3×
“Although label-free multiphoton IVM is striking for its nonperturbative character, its widespread uses have been mired mainly due to the inadequate contrast of each imaging technique and difficulties to combine them [150].”
BackgroundMethodInfluentialHan, S.-S., Li, Z.-Y., Zhu, J.-Y., Han, K., Zeng, Z.-Y., Hong, W., Li, W.-X., Jia, H.-Z., Liu, Y., Zhuo, R.-X., et al. (2015) · Small · doi:10.1002/smll.201402865 · Cited by 269
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268 · cited 1×
“This strategy includes direct depletion of ECM components, inhibition of the synthesis of ECM components, or modulation of ECM-associated cells [156].”
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260 · cited 1×
“Remodeling of tumor vasculature utilizing angiogenic mediators or external stimuli modulates the function of the vessels affecting infiltration and disruption [90].”
BackgroundCh, G., Charalabopoulos, A., Stagikas, D., Charalabopoulos, K., & Batistatou, A. K. (2007) · PubMed Central · Cited by 250
Liu, R., Xiao, W., Hu, C., Xie, R., & Gao, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.005 · Cited by 250 · cited 2×
“Dual targeting approaches with EGFR and CD44 are also effective for enhancing EPR-based drug delivery, which may decrease the uncertainty of a single targeting strategy [54,55].”
BackgroundSun, Y., Zhao, D., Wang, G., Wang, Y., Cao, L., Sun, J., Jiang, Q., & He, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.004 · Cited by 250
Lv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08051 · Cited by 235 · cited 1×
“The study showed that the integration of TME-targeting with HA-based nanodrugs with a TME regulator is a prospective approach for cancer therapy [53].”
BackgroundCancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls
Nakamura, H., Jun, F., & Maeda, H. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.955011 · Cited by 232 · cited 1×
“Further, high-intensity focused ultrasound may be utilized to improve the EPR effect of nanodrugs in tumors [76].”
BackgroundHuang, J., Frischer, J. S., Serur, A., Kadenhe, A., Yokoi, A., McCrudden, K. W., New, T., O'Toole, K., Zabski, S., Rudge, J. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432908100 · Cited by 227 · cited 1×
“For example, NO-releasing NPs integrating a photosensitizer (IR780) and chemotherapeutic paclitaxel remarkably reduced tumor growth by enhancing tumor vascular permeability and leading to the inhibition of tumors [91,92].”
BackgroundDiagaradjane, P., Shetty, A., Wang, J. C., Elliott, A. M., Schwartz, J., Shentu, S., Park, H. C., Deorukhkar, A., Stafford, R. J., Cho, S. H., et al. (2008) · Nano Letters · doi:10.1021/nl080496z · Cited by 215
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214 · cited 1×
“TGF-β plays a crucial role in TME renovation, controlling angiogenesis, and preventing the expansion of the T cells [85,86].”
BackgroundLiu, J., Liang, H., Li, M., Luo, Z., Zhang, J., Guo, X., & Cai, K. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.12.003 · Cited by 210
Chemical Tumor-Targeting of Nanoparticles Based on Metabolic Glycoengineering and Click Chemistry
Lee, S., Koo, H., Na, J. H., Han, S. J., Min, H. S., Lee, S. J., Kim, S. H., Yun, S. H., Jeong, S. Y., Kwon, I. C., et al. (2014) · ACS Nano · doi:10.1021/nn406584y · Cited by 206 · cited 1×
“The strategy exhibited a way to overwhelm the heterogeneity of intensity of the EPR effect and to enhance the EPR-based drug delivery [82].”
BackgroundHu, X.-X., He, P.-P., Qi, G.-B., Gao, Y.-J., Lin, Y.-X., Yang, C., Yang, P.-P., Hao, H., Wang, L., & Wang, H. (2017) · ACS Nano · doi:10.1021/acsnano.7b00781 · Cited by 205 · cited 1×
“Further, artificial ECM may also be built utilizing laminin protein-mimic peptidebased NPs [83].”
BackgroundPorta Siegel, T., Hamm, G., Bunch, J., Cappell, J., Fletcher, J. S., & Schwamborn, K. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1267-y · Cited by 187 · cited 1×
“On tissue and cellular scale, imaging combination of optical imaging and mass spectrometry imaging techniques have demonstrated promise [139].”
BackgroundArterial thromboembolic events preceding the diagnosis of cancer in older persons
Navi, B. B., Reiner, A. S., Kamel, H., Iadecola, C., Okin, P. M., Tagawa, S. T., Panageas, K. S., & DeAngelis, L. M. (2019) · Blood · doi:10.1182/blood-2018-06-860874 · Cited by 179 · cited 1×
“As tumors grow, the coagulation system is also activated, which is responsible for the poor accumulation of drugs due to avascular areas and embolization of tumor tissues [32].”
BackgroundAn Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
Sharifi, M., Cho, W. C., Ansariesfahani, A., Tarharoudi, R., Malekisarvar, H., Sari, S., Bloukh, S. H., Edis, Z., Amin, M., Gleghorn, J. P., et al. (2022) · Cancers · doi:10.3390/cancers14122868 · Cited by 178 · cited 1×
“Nanodrugs utilized in anticancer therapy have the benefit of their privileged assemblage in leaky tumors due to the EPR effect [15].”
BackgroundNew topics in bradykinin research
Maurer, M., Bader, M., Bas, M., Bossi, F., Cicardi, M., Cugno, M., Howarth, P., Kaplan, A., Kojda, G., Leeb‐Lundberg, F., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02686.x · Cited by 176
Huang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176
Hypoxia and hypoxia inducible factors in tumor metabolism
Zeng, W., Liu, P., Pan, W., Singh, S. R., & Wei, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.032 · Cited by 170 · cited 1×
“Hypoxia (oxygen-deficient environment) is the consequence of the high demand for nutrients and oxygen in malignant tumors [58].”
BackgroundShim, M. K., Park, J., Yoon, H. Y., Lee, S., Um, W., Kim, J.-H., Kang, S.-W., Seo, J.-W., Hyun, S.-W., Park, J. H., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.032 · Cited by 169 · cited 1×
“It was then activated by cathepsin B, which is overexpressed in tumors, by releasing free DOX in tumors [70].”
BackgroundMaeda, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030229 · Cited by 167
Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation
Bekassy, Z., Lopatko Fagerström, I., Bader, M., & Karpman, D. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-021-00634-8 · Cited by 167 · cited 1×
“The activation of plasma and tissue kallikreins by factor X II, also known as an important initiator of blood coagulation and aminopeptidases, respectively, results in the synthesis of bradykinins [107].”
BackgroundZhou, Y., Ren, X., Hou, Z., Wang, N., Jiang, Y., & Luan, Y. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00480d · Cited by 165 · cited 1×
“However, the hypoxic conditions in the tumor microenvironment and improper blood supply to the tumor mass present as a major barrier in the clinical progress of this physical therapy [118].”
BackgroundHAE Pathophysiology and Underlying Mechanisms
Zuraw, B. L., & Christiansen, S. C. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8561-8 · Cited by 164 · cited 1×
“Activation of bradykinin receptors B1 and B2 results in increased vasodilation, disruption of endothelial adherens junctions, and actomyosin cytoskeletal contraction of endothelial cells [39].”
BackgroundAdvantages and Limitations of Current Techniques for Analyzing the Biodistribution of Nanoparticles
Arms, L., Smith, D. W., Flynn, J., Palmer, W., Martin, A., Woldu, A., & Hua, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00802 · Cited by 159
Zhang, C., Li, J., Xiao, M., Wang, D., Qu, Y., Zou, L., Zheng, C., & Zhang, J. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.03.110 · Cited by 156 · cited 1×
“By modulating tumor blood vessels utilizing nanostructures including NPs, liposomes, micelles, polymers, and nanobiomaterials for drug delivery, the EPR effect may be potentially enhanced for different cancer therapies, such as pancreatic cancer and ulcerative colitis [14,16].”
BackgroundImage guided therapy: The advent of theranostic agents
Terreno, E., Uggeri, F., & Aime, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.028 · Cited by 153 · cited 2×
“As a result, PET and SPECT-based probes are less suitable for imaging drug release and optical and MRI-based contrast agents hold landscapes better for this purpose [130].”
BackgroundMethodModulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152 · cited 3×
“Types of EPR-effect enhancers and mechanism of action [44].”
BackgroundNear infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy
Fan, Z., Chang, Y., Cui, C., Sun, L., Wang, D. H., Pan, Z., & Zhang, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04763-y · Cited by 151 · cited 1×
“The nanoassembly demonstrated enhanced accumulation in tumors through αvβ3 binding and the EPR effect, causing improved therapeutic efficiency [47].”
BackgroundYoung, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
RGD peptide-based non-viral gene delivery vectors targeting integrin α v β 3 for cancer therapy
Fu, S., Xu, X., Ma, Y., Zhang, S., & Zhang, S. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1455841 · Cited by 139 · cited 1×
“Thus, targeting αvβ3 enhances the delivery of NPs to the angiogenic vessels, improving the extravasation of nanodrugs in tumors [46].”
BackgroundThe (pro)renin receptor in health and disease
Ichihara, A., & Yatabe, M. S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0160-5 · Cited by 137 · cited 1×
“These reactions mediated by angiotensin-converting enzymes (ACE-I and ACE-II) play a critical role in the regulation of blood pressure, inflammation, vascular permeation, coagulation, and fibrosis [105].”
BackgroundThe role of kinin receptors in cancer and therapeutic opportunities
da Costa, P. L. N., Sirois, P., Tannock, I. F., & Chammas, R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.12.009 · Cited by 133
Protein nanocages that penetrate airway mucus and tumor tissue
Huang, X., Chisholm, J., Zhuang, J., Xiao, Y., Duncan, G., Chen, X., Suk, J. S., & Hanes, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705407114 · Cited by 131
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
Pérez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2016) · Nature Communications · doi:10.1038/ncomms11838 · Cited by 128 · cited 2×
“Heterogeneous drug distribution happens for drugs of almost all sizes, and therapy shows no desired effect [131,132].”
BackgroundMethodMultimodality imaging in nanomedicine and nanotheranostics
Li, X., Li, X., Zhang, X.-N., Li, X.-D., Chang, J., Zhang, X.-N., Li, X.-D., & Chang, J. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0055 · Cited by 126 · cited 1×
“Different types of NPs for multimodal imaging have been established such as modified Gd2O3 NPs, gold NPs, 64CuInS/ZnS QDs, Bi2S3 NPs, and liposomal nanocarrier conjugated 99mTc [137,138].”
BackgroundCancer nanomedicine: Addressing the dark side of the enhanced permeability and retention effect
Huynh, E., & Zheng, G. (2015) · Nanomedicine · doi:10.2217/nnm.15.86 · Cited by 125
Chen, J., Ouyang, J., Chen, Q., Deng, C., Meng, F., Zhang, J., Cheng, R., Lan, Q., & Zhong, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06879 · Cited by 124 · cited 1×
“Dual targeting approaches with EGFR and CD44 are also effective for enhancing EPR-based drug delivery, which may decrease the uncertainty of a single targeting strategy [54,55].”
BackgroundSnipstad, S., Sulheim, E., de Lange Davies, C., Moonen, C., Storm, G., Kiessling, F., Schmid, R., & Lammers, T. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1547279 · Cited by 117
Sun, Q., You, Q., Wang, J., Liu, L., Wang, Y., Song, Y., Cheng, Y., Wang, S., Tan, F., & Li, N. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b13651 · Cited by 109 · cited 1×
“Utilizing a duple of fluorescent and MRI agents, the high sensitivity of the fluorescent was accompanied by the MRI’s aptitude for deep-tissue imaging and high spatial and temporal resolution [142,143].”
BackgroundKang, Y., Kim, J., Park, J., Lee, Y. M., Saravanakumar, G., Park, K. M., Choi, W., Kim, K., Lee, E., Kim, C., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119297 · Cited by 108
Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106 · cited 1×
“The EPR-based drug delivery is allied with the ECM heterogeneity and physiologic sceneries in the tumors [43].”
BackgroundTargeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy
Wu, J., Tang, Y., & Liang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172042 · Cited by 105 · cited 1×
“Further, the regulation of tumor blood vessels in TME may be attained by the delivery of anti-VEGF antibodies or VEGF receptor inhibitors [93,94].”
BackgroundChen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104 · cited 1×
“This improved the accumulation of human serum albumin-bound paclitaxel (HAS-PTX) in vivo in tumor-bearing mice such as head and neck carcinoma cells (SCC7), colon carcinoma cells (CT26), and breast cancer cells (4T1) [27].”
BackgroundPET-MR and SPECT-MR multimodality probes: Development and challenges
Yang, C.-T., Ghosh, K. K., Padmanabhan, P., Langer, O., Liu, J., Eng, D. N. C., Halldin, C., & Gulyás, B. (2018) · Theranostics · doi:10.7150/thno.26610 · Cited by 101 · cited 1×
“Different types of NPs for multimodal imaging have been established such as modified Gd2O3 NPs, gold NPs, 64CuInS/ZnS QDs, Bi2S3 NPs, and liposomal nanocarrier conjugated 99mTc [137,138].”
BackgroundAbumanhal-Masarweh, H., Koren, L., Zinger, A., Yaari, Z. A., Krinsky, N., Kaneti, G., Dahan, N., Lupu-Haber, Y., Suss-Toby, E., Weiss‐Messer, E., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.004 · Cited by 100 · cited 2×
“Several enzymes, such as MMP and caspase, have been applied to enhance the EPRbased drug delivery of nanodrugs [69,71].”
BackgroundAshton, J. R., Castle, K. D., Qi, Y., Kirsch, D. G., West, J. L., & Badea, C. T. (2018) · Theranostics · doi:10.7150/thno.22621 · Cited by 97 · cited 1×
“NPs with RGD, that target TME, in integration with RT, have demonstrated that the radiation can influence endothelial cells and blood vessels and enhance the EPR effect as well as the therapeutic response to chemotherapy [77].”
BackgroundMiller, M. A., Mikula, H., Luthria, G., Li, R., Kronister, S., Prytyskach, M., Kohler, R. H., Mitchison, T., & Weissleder, R. (2018) · ACS Nano · doi:10.1021/acsnano.8b07954 · Cited by 97 · cited 1×
“Palladium encapsulated in NPs exhibited effective catalytic activity in animal models in vivo [84].”
BackgroundIslam, W., Fang, J., Imamura, T., Etrych, T., Subr, V., Ulbrich, K., & Maeda, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0696 · Cited by 95 · cited 1×
“5–2 times improved delivery and 2–4 fold antitumoreffects of model drugs [108]”
BackgroundDatta, N. R., Krishnan, S., Speiser, D. E., Neufeld, E., Kuster, N., Bodis, S., & Hofmann, H. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.016 · Cited by 92
Imaging of anticancer drug action in single cells
Miller, M. A., & Weissleder, R. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.41 · Cited by 92 · cited 1×
“These new modalities will likely extend possibilities for the imaging of nanodrugs [147,148].”
BackgroundYu, Q., Tang, X., Zhao, W., Qiu, Y., He, J., Wan, D., Li, J., Wang, X., He, X., Liu, Y., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.002 · Cited by 90
Zou, P., Chen, H., Paholak, H. J., & Sun, D. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4002393 · Cited by 88 · cited 3×
“Heterogeneous drug distribution happens for drugs of almost all sizes, and therapy shows no desired effect [131,132].”
BackgroundMethodXiao, W., Ruan, S., Yu, W., Wang, R., Hu, C., Liu, R., & Gao, H. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00475 · Cited by 84 · cited 1×
“used a combination of cediranib (VEGFR TKI) and enzyme-responsive size changeable gold nanoparticles (from around 40 nm to 300 nm upon enzymatic activity) [29].”
MethodInfante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.327 · Cited by 83 · cited 1×
“HA-degradable PEGPH20 in integration with gemcitabine has demonstrated enhanced therapeutic effects in animal models [56,57].”
BackgroundHan, H., Lee, H., Kim, K., & Kim, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.022 · Cited by 80
Induced Phenotype Targeted Therapy: Radiation-Induced Apoptosis-Targeted Chemotherapy
Lee, B. S., Cho, Y. W., Kim, G. C., Lee, D. H., Kim, C. J., Kil, H. S., Chi, D. Y., Byun, Y., Yuk, S. H., Kim, K., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju403 · Cited by 76 · cited 2×
“The apoptosis induction is primarily necessary to originate the overexpression of caspase-3 in tumors in the case of caspase-3-responsive prodrugs [72].”
BackgroundSix-color intravital two-photon imaging of brain tumors and their dynamic microenvironment
Ricard, C., & Debarbieux, F. C. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00057 · Cited by 75
Rodrigues, R. O., Baldi, G., Doumett, S., García‐Hevia, L., Gallo, J., Bañobre‐López, M., Dražić, G., Calhelha, R. C., Ferreira, I. C. F. R., Lima, R. A., et al. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.07.060 · Cited by 74
Badea, C. T., Clark, D. P., Holbrook, M., Srivastava, M., Mowery, Y., & Ghaghada, K. B. (2019) · Physics in Medicine & Biology · doi:10.1088/1361-6560/ab03e2 · Cited by 74 · cited 1×
“Thus, DCE-CT is beneficial for identifying patients expected to respond to liposomal drug therapy [134].”
BackgroundImaging-assisted anticancer nanotherapy
Dasgupta, A., Biancacci, I., Kiessling, F., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.38288 · Cited by 74 · cited 4×
“Imaging assists in determining nanodrug distribution, target tumor site accumulation, and drug release [126].”
BackgroundInfluentialA switchable NO-releasing nanomedicine for enhanced cancer therapy and inhibition of metastasis
Xu, Y., Ren, H., Liu, J., Wang, Y., Meng, Z., He, Z., Miao, W., Chen, G., & Li, X. (2019) · Nanoscale · doi:10.1039/c9nr00732f · Cited by 71 · cited 1×
“For example, NO-releasing NPs integrating a photosensitizer (IR780) and chemotherapeutic paclitaxel remarkably reduced tumor growth by enhancing tumor vascular permeability and leading to the inhibition of tumors [91,92].”
Backgroundde Maar, J. S., Sofias, A. M., Porta Siegel, T., Vreeken, R. J., Moonen, C., Bos, C., & Deckers, R. (2020) · Theranostics · doi:10.7150/thno.38625 · Cited by 71 · cited 8×
“Thus, selecting astutely and integrating multiple techniques will deliver sufficient information on therapeutic NPs distribution in tumors [19].”
BackgroundMethodInfluentialMonitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles
Biancacci, I., De Lorenzi, F., Theek, B., Bai, X., May, J., Consolino, L., Baues, M., Moeckel, D., Gremse, F., von Stillfried, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202103745 · Cited by 68 · cited 5×
“Cancer nanodrugs rely on the EPR effect for effective accumulation into the target site [2].”
BackgroundInfluentialLee, S., Jung, S., Koo, H., Na, J. H., Yoon, H. Y., Shim, M. K., Park, J., Kim, J.-H., Lee, S., Pomper, M. G., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.025 · Cited by 63 · cited 1×
“An artificial azide reporter emerging from the metabolic precursor (Ac4ManNAz) can be introduced on the tumor cell surface [80,81].”
BackgroundHsu, J. C., Naha, P. C., Lau, K. C., Chhour, P., Hastings, R., Moon, B. F., Stein, J. M., Witschey, W. R. T., McDonald, E. S., Maidment, A. D. A., et al. (2018) · Nanoscale · doi:10.1039/c8nr03741h · Cited by 63 · cited 1×
“For achieving multiscale imaging evidence, optical imaging and MSI have been harmonized with clinical imaging [141].”
MethodFang, J., Islam, R., Islam, W., Yin, H., Subr, V., Etrych, T., Ulbrich, K., & Maeda, H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070343 · Cited by 63 · cited 1×
“5–2 times greater tumor delivery of nanodrug when combined with generators of CO [109]”
BackgroundLow-intensity focused ultrasound-augmented Cascade chemodynamic therapy via boosting ROS generation
Deng, L., Liu, M., Sheng, D., Luo, Y., Wang, D., Yu, X., Wang, Z., Ran, H., & Li, P. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120710 · Cited by 63
Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data
Abdelmoula, W. M., Regan, M. S., Lopez, B. G. C., Randall, E. C., Lawler, S., Mladek, A. C., Nowicki, M. O., Marin, B. M., Agar, J. N., Swanson, K. R., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00854 · Cited by 62 · cited 1×
“Thus, a combination of MSI with other techniques is prospective for bridging the gaps between unalike scales [145,146].”
BackgroundsiRNA in ovarian cancer – Delivery strategies and targets for therapy
van den Brand, D., Mertens, V., Massuger, L. F. A. G., & Brock, R. E. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.012 · Cited by 60 · cited 1×
“A cationic micellar NP combines HIF-1α siRNA and the NP-siHIF nanosystem that effectively reduced tumor cell proliferation, angiogenesis, and migration, and hindered tumor growth as well as reduced MDR1 expression both in vitro and in vivo [63,64].”
BackgroundImproving nanotherapy delivery and action through image-guided systems pharmacology
Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Theranostics · doi:10.7150/thno.37215 · Cited by 60 · cited 3×
“A harmonious integration of imaging with system-level computational approaches for the clinical development of nanodrugs has been growing as technologies are improving for increased resolution, multiplexing, and examining the heterogeneity at the single-cell level [18].”
BackgroundInfluentialThinking about Enhanced Permeability and Retention Effect (EPR)
Leporatti, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081259 · Cited by 58 · cited 1×
“ducted in appropriate models, the combination of nanomedicine with the EPR-enhancing strategy must be designed for a certain type of cancer, and side effects of EPR enhancing agents must be taken into consideration [154].”
BackgroundLiposomes with cyclic RGD peptide motif triggers acute immune response in mice
Wang, X., Wang, H., Jiang, K., Zhang, Y., Zhan, C., Ying, M., Zhang, M., Lu, L., Wang, R., Wang, S., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.003 · Cited by 56 · cited 2×
“However, the RGD-based peptide delivery system may be allied with severe immune activation [48].”
BackgroundDoxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy
Khaliq, N. U., Sandra, F. C., Park, D. Y., Lee, J., Oh, K. S., Kim, D., Byun, Y., Kim, I.-S., Kwon, I. C., Kim, S. Y., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.056 · Cited by 54 · cited 1×
“The Onivyde drug is based on irinotecan, and it has demonstrated enhanced response and therapeutic efficiency in clinical use for cancer therapy [72,73].”
BackgroundBanerjee, S. R., Foss, C. A., Horhota, A., Pullambhatla, M., McDonnell, K., Zale, S., & Pomper, M. G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01485 · Cited by 54 · cited 1×
“For visualization and quantification of nanodrug circulation behavior, biodistribution, and target tumor aggregation, imaging agents have been encapsulated within or conjugated to NPs and imaging them utilizing different imaging techniques [129].”
MethodJain, S., Pathak, K., & Vaidya, A. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.05.077 · Cited by 53 · cited 1×
“A cationic micellar NP combines HIF-1α siRNA and the NP-siHIF nanosystem that effectively reduced tumor cell proliferation, angiogenesis, and migration, and hindered tumor growth as well as reduced MDR1 expression both in vitro and in vivo [63,64].”
BackgroundBlanco, V. M., Chu, Z., Vallabhapurapu, S. D., Sulaiman, M. K., Kendler, A., Rixe, O., Warnick, R. E., Franco, R. S., & Qi, X. (2014) · Oncotarget · doi:10.18632/oncotarget.2214 · Cited by 52 · cited 1×
“A liposomal protein, Saposin C bonded to phosphatidylserine, may be used to fabricate NPs to bind to hypoxic TME [60,61].”
BackgroundYoon, H. Y., Shin, M. L., Shim, M. K., Lee, S., Na, J. H., Koo, H., Lee, H., Kim, J.-H., Lee, K. Y., Kim, K., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01083 · Cited by 50 · cited 1×
“An artificial azide reporter emerging from the metabolic precursor (Ac4ManNAz) can be introduced on the tumor cell surface [80,81].”
BackgroundNovel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update
Mohammadzadeh, V., Rahiman, N., Hosseinikhah, S. M., Barani, M., Rahdar, A., Jaafari, M. R., Sargazi, S., Zirak, M. R., Pandey, S., Bhattacharjee, R., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103459 · Cited by 50 · cited 2×
“By modulating tumor blood vessels utilizing nanostructures including NPs, liposomes, micelles, polymers, and nanobiomaterials for drug delivery, the EPR effect may be potentially enhanced for different cancer therapies, such as pancreatic cancer and ulcerative colitis [14,16].”
BackgroundZhang, B., Jin, K., Jiang, T., Wang, L., Shen, S., Luo, Z., Tuo, Y., Liu, X., Hu, Y., & Pang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-09520-7 · Cited by 49 · cited 1×
“In addition, celecoxib a cyclooxygenase-2 (COX-2) inhibitors also act as an angiogenesis inhibitor and result in vascular normalization and improved EPR effect in the tumor site [30].”
BackgroundMao, C., Li, F., Zhao, Y., Debinski, W., & Ming, X. (2018) · Theranostics · doi:10.7150/thno.29580 · Cited by 48 · cited 1×
“However, combination therapy of nanodrugs and PDT can inhibit resistant cancer cells by improving the tumor infiltration of the nanodrugs [74].”
BackgroundMMP-2-Controlled Transforming Micelles for Heterogeneic Targeting and Programmable Cancer Therapy
Wang, Z., Wang, Y., Jia, X., Han, Q., Qian, Y., Li, Q., Xiang, J., Wang, Q., Hu, Z., & Wang, W. (2019) · Theranostics · doi:10.7150/thno.30915 · Cited by 48 · cited 1×
“Several enzymes, such as MMP and caspase, have been applied to enhance the EPRbased drug delivery of nanodrugs [69,71].”
BackgroundEPR or no EPR? The billion-dollar question
Wang, A. Z. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8108 · Cited by 44 · cited 1×
“Today, the EPR remains a controversial topic in nanomedicine [152].”
BackgroundFibrin degradation by rtPA enhances the delivery of nanotherapeutics to A549 tumors in nude mice
Zhang, B., Jiang, T., She, X., Shen, S., Wang, S., Deng, J., Shi, W., Mei, H., Hu, Y., Pang, Z., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.015 · Cited by 44 · cited 1×
“The pretreatment group showed a higher accumulation and enhanced penetration depth of 115 nm nanoparticles at the tumor site in comparison to the saline group [37].”
BackgroundRyu, J. H., Shin, M., Kim, S. A., Lee, S., Kim, H., Koo, H., Kim, B., Song, H. K., Kim, S. H., Choi, K., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.026 · Cited by 42 · cited 1×
“EGF ligand is promising for targeting EGFR in tumors [50].”
BackgroundHarnessing Extracellular Matrix Biology for Tumor Drug Delivery
Subrahmanyam, N., & Ghandehari, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020088 · Cited by 42
The Potential Role of Sildenafil in CancerManagement Through EPR Augmentation
Haider, M., Elsherbeny, A., Pittalà, V., Fallica, A. N., Alghamdi, M. A., & Greish, K. (2021) · doi:10.20944/preprints202104.0679.v1 · Cited by 42
Zhang, B., Shi, W., Jiang, T., Wang, L., Mei, H., Lu, H., Hu, Y., & Pang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11546 · Cited by 41 · cited 1×
“Another TKI, Imatinib, inhibits VEGF-independent angiogenesis and also improves the delivery of nanoparticles to the tumor site, which was observed in A459 xenograft tumor models (lung carcinoma) [28].”
BackgroundZhang, B., Jiang, T., Tuo, Y., Jin, K., Luo, Z., Shi, W., Mei, H., Hu, Y., Pang, Z., & Jiang, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.007 · Cited by 41
Yao, M., Ma, X., Zhang, X., Shi, L., Liu, T., Liang, X., Zhao, H., Li, X., Li, L., Gao, H., et al. (2019) · Theranostics · doi:10.7150/thno.29989 · Cited by 39
Kirtane, A. R., Sadhukha, T., Kim, H., Khanna, V., Koniar, B., & Panyam, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1646 · Cited by 38 · cited 1×
“However, improved the penetration of Doxil® into B16F10 tumors [38].”
BackgroundRen, H., Yang, Q., Yong, J., Fang, X., Yang, Z., Liu, Z., Jiang, X., Miao, W., & Li, X. (2021) · Biomaterials Science · doi:10.1039/d0bm02028a · Cited by 37 · cited 1×
“Human serum albumin nanoparticles containing CO donor and photosensitizer (MnCO and IR780) Combined CO gas therapy and phototherapy significantly inhibited the growth of tumors through synergism [110]”
BackgroundZhang, Q., Wang, N., Ma, M., Luo, Y., & Chen, H. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800152 · Cited by 36 · cited 1×
“Sonosensitizer-containing NPs were developed to enable transferrin-facilitated endocytosis for deep tissue infiltration [75].”
BackgroundContrast Agent Mass Spectrometry Imaging Reveals Tumor Heterogeneity
Tata, A., Zheng, J., Ginsberg, H. J., Jaffray, D. A., Ifa, D. R., & Zarrine-Afsar, A. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01992 · Cited by 34 · cited 2×
“Integration of 2D MSI with 3D MRI was able to monitor MRI contrast agents [145].”
BackgroundFeng, T., Zhou, L., Wang, Z., Li, C., Zhang, Y., Lin, J., Lu, D., & Huang, P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119709 · Cited by 33
EPR Effect-Based Tumor Targeted Nanomedicine: A Promising Approach for Controlling Cancer
Fang, J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010095 · Cited by 31 · cited 2×
“Therefore, tumor blood vessels are leaky compared to normal blood vessels due to the defective endothelial cells and more vascular permeability, as well as vastly expressed vascular mediators including bradykinin, NO, and VEGF, resulting in selective accumulation of nanodrugs into tumor tissues with little or no distr…”
BackgroundPenafuerte, C., Bautista-Lopez, N., Bouchentouf, M., Birman, E., Forner, K., & Galipeau, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003816 · Cited by 30 · cited 1×
“TGF-β plays a crucial role in TME renovation, controlling angiogenesis, and preventing the expansion of the T cells [85,86].”
BackgroundLiang, Y., Peng, J., Li, N., Yu-Wai-Man, C., Wang, Q., Xu, Y., Wang, H., Tagalakis, A. D., & Du, Z. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.09.018 · Cited by 30 · cited 1×
“Dual targeting approaches with EGFR and CD44 are also effective for enhancing EPR-based drug delivery, which may decrease the uncertainty of a single targeting strategy [54,55].”
BackgroundIslam, W., Kimura, S., Islam, R., Harada, A., Ono, K., Fang, J., Niidome, T., Sawa, T., & Maeda, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060487 · Cited by 30 · cited 1×
“Isosorbide dinitrate and Sildenafil The therapeutic efficacy of the drug was increased 2–4 fold after blood flow restoration through the generation of NO [9]”
BackgroundPark, J., Pei, Y., Hyun, H., Castanares, M. A., Collins, D. S., & Yeo, Y. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.037 · Cited by 29 · cited 1×
“Utilizing a duple of fluorescent and MRI agents, the high sensitivity of the fluorescent was accompanied by the MRI’s aptitude for deep-tissue imaging and high spatial and temporal resolution [142,143].”
BackgroundBørresen, B., Hansen, A. E., Fliedner, F. P., Henriksen, J. R., Elema, D. R., Brandt-Larsen, M., Kristensen, L. K., Kristensen, A. T., Andresen, T. L., & Kjær, A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s239172 · Cited by 28 · cited 1×
“Molecular imaging modalities have the potential for detecting EPR effects to formulate better therapeutic NPs and select patients with a high EPR effect [122].”
BackgroundNanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma
Aldea, M. D., Florian, I. A., Kacsó, G., Craciun, L., Boca, S., Şoriţău, O., & Florian, I. Ş. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1947-8 · Cited by 27 · cited 1×
“A liposomal protein, Saposin C bonded to phosphatidylserine, may be used to fabricate NPs to bind to hypoxic TME [60,61].”
BackgroundZhu, L., Dai, Y., Gao, L., & Zhao, Q. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s309062 · Cited by 27
EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model
Zalba, S., Contreras, A. M., Merino, M., Navarro, I., de Ilarduya, C. T., Trocóniz, I. F., Koning, G., & Garrido, M. J. (2016) · Nanomedicine · doi:10.2217/nnm.15.208 · Cited by 26 · cited 1×
“EGF-liposome conjugates remarkably reduced the IC50 value of oxaliplatin in colorectal cancer cells which overexpressed ERFR, though not in the EGFR-negative colorectal cancer cells [51].”
BackgroundHypoxia-Responsive Copolymer for siRNA Delivery
Perche, F., Biswas, S., Patel, N. R., & Torchilin, V. P. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3148-4_12 · Cited by 26 · cited 1×
“A hypoxia-responsive copolymer system was developed for siRNA delivery to tumors [65].”
MethodSelf-citationStrittmatter, N., Moss, J. I., Race, A. M., Sutton, D., Canales, J. R., Ling, S., Wong, E., Wilson, J., Smith, A., Howes, C., et al. (2022) · Theranostics · doi:10.7150/thno.68000 · Cited by 25 · cited 1×
“The delivered nanodrug was associated with tumor sites higher in macrophages, as well as high stromal regions [19,144].”
BackgroundDou, Y. N., Chaudary, N., Chang, M. C., Dunne, M., Huang, H., Jaffray, D. A., Milosevic, M., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.039 · Cited by 21 · cited 1×
“The differences in the composition of TME may lead to intertumoral heterogeneity in nanodrug aggregation and therapy outcome [124].”
BackgroundFuchs, K., Kiss, A., Bize, P. E., Duran, R., Denys, A., Hopfgartner, G., Borchard, G., & Jordan, O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.042 · Cited by 21 · cited 1×
“Fluorescence MSI has been integrated to depict local drug release and record unlabeled therapeutic drug circulation, which is offered to track the drug metabolites [140].”
BackgroundHigh-resolution 3D visualization of nanomedicine distribution in tumors
Moss, J. I., Barjat, H., Emmas, S.-A., Strittmatter, N., Maynard, J., Goodwin, R. J. A., Storm, G., Lammers, T., Puri, S., Ashford, M. B., et al. (2020) · Theranostics · doi:10.7150/thno.37178 · Cited by 19 · cited 1×
“Further, high-resolution ex vivo μ-CT was utilized to study the spatial distribution of drugs in different tumor models [127].”
MethodQi, B., Crawford, A. J., Wojtynek, N. E., Talmon, G. A., Hollingsworth, M. A., Ly, Q. P., & Mohs, A. M. (2020) · Theranostics · doi:10.7150/thno.40688 · Cited by 18 · cited 1×
“The results exhibited that the molecular weight of HA and the properties of conjugated dyes influence the imaging outcome [128].”
BackgroundIonizing Radiation-Induced Release from Poly(ε-caprolactone- b -ethylene glycol) Micelles
Liu, H., Laan, A. C., Plomp, J., Parnell, S. R., Men, Y., Dalgliesh, R. M., Eelkema, R., & Denkova, A. G. (2021) · ACS Applied Polymer Materials · doi:10.1021/acsapm.0c01258 · Cited by 18
Yin, C., Wang, S., Ren, Q., Shen, X., Chen, X., Liu, Y., & Liu, S. (2019) · 中国科学通报:英文版 · doi:10.1016/j.scib.2019.04.017 · Cited by 16
Research works printed but not linked: 1
- Yin, 2014, Enhanced Permeability and Retention (EPR) Effect Based Tumor Targeting: The Concept, Application and Prospect, JSM Clin. Oncol. Res., 2, 1010
Cited by
Khan, M. S., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., Sahebkar, A., & Kesharwani, P. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214636 · Cited by 143
Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting
Spada, A., & Gerber‐Lemaire, S. (2025) · Nanomaterials · doi:10.3390/nano15030158 · Cited by 92
Shestovskaya, M. V., Luss, A. L., Si, B., Makarov, V. V., & Keskinov, A. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102406 · Cited by 60
Nanotechnology Driven Innovations in Modern Pharmaceutics: Therapeutics, Imaging, and Regeneration
Parvin, N., Aslam, M., Alam, M. N., & Mandal, T. K. (2025) · Nanomaterials · doi:10.3390/nano15221733 · Cited by 77
“Future research should focus on integrating EPR-based delivery with tumor microenvironment modulation and personalized approaches to maximize therapeutic outcomes [86].”
Graphene Quantum Dots from Natural Carbon Sources for Drug and Gene Delivery in Cancer Treatment
Osorio, H. M., Castillo-Solís, F., Barragán, S. Y., Rodríguez-Pólit, C., & González‐Pastor, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910539 · Cited by 49
“Also, these nanoscale vectors can remain at the tumor site given their enhanced permeability and retention (EPR) effect [17,18].”
Background
Metadata
- Authors
- Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2023-02-23
- Volume
- 13
- Issue
- 3
- Pages
- 389
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC10051487
- OpenAlex
- W4321601715
- Cited by
- 98
- References
- 167
- Citations by year
- 2026: 34 · 2025: 33 · 2024: 26 · 2023: 5
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor microenvironment, nanomedicine, anticancer drug delivery, tumor targeting, tumor imaging, animal models, clinical translation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.